"The Buzz" Show: Novavax (NASDAQ: NVAX) to Develop A Combination Covid-19/Flu Vaccine | Financial Buzz

“The Buzz” Show: Novavax (NASDAQ: NVAX) to Develop A Combination Covid-19/Flu Vaccine

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Novavax to Develop A Combination Covid-19/Flu Vaccine”

Novavax (NASDAQ: NVAX), Inc. is up over 7% during early morning trading after the company announced the formation of a leadership team to advance NanoFlu to regulatory licensure.

The team will focus on obtaining licensure for NanoFlu from the FDA and other global authorities, as well as evaluate the development of a pentavalent NanoFlu/NVX-CoV2373 post-pandemic influenza/COVID-19 combination vaccine.

Novavax is a late-stage biotechnology company that promotes improved global health through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.

For more information, please visit: Novavax, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.